Proanthocyanidins Prevent High Glucose-Induced Eye Malformation by Restoring Pax6 Expression in Chick Embryo

Rui-Rong Tan1, Shi-Jie Zhang2,3, Yi-Fang Li4

  • 1Anti-stress and Health Center, Pharmacy College, Jinan University, Guangzhou 510632, China. tanruirong@foxmail.com.

Nutrients
|August 12, 2015
PubMed

Insights

Proanthocyanidins protect against gestational diabetes-induced eye malformations in chick embryos by restoring Pax6 gene expression and reducing oxidative stress. This natural compound shows promise for preventing fetal eye developmental issues.

Area of Science:

  • Developmental Biology
  • Endocrinology
  • Pharmacology

Background:

  • Gestational diabetes mellitus (GDM) is a significant cause of congenital malformations, particularly affecting fetal eye development.
  • There is a critical need for therapeutic interventions to mitigate GDM's adverse effects on embryonic development.

Purpose of the Study:

  • To investigate the protective effects of proanthocyanidins on eye development in a chick embryo model of GDM.
  • To explore the underlying mechanisms, including oxidative stress and key gene regulation.

Main Methods:

  • A GDM model was established in chick embryos using high glucose exposure.
  • Proanthocyanidins were administered via air sac injection.
  • Eye malformations, oxidative stress markers, glucose levels, and Pax6 gene expression were assessed.

Main Results:

  • Proanthocyanidins significantly prevented high glucose-induced eye malformations and oxidative stress.
  • The protective effects were comparable to edaravone.
  • Proanthocyanidins restored the down-regulation of the eye development gene Pax6 caused by high glucose.
  • Proanthocyanidins did not alter glucose concentration in the embryo eye.

Conclusions:

  • Proanthocyanidins demonstrate a protective effect against GDM-induced eye malformations in a chick embryo model.
  • The mechanism involves mitigating oxidative stress and restoring Pax6 gene expression.
  • Proanthocyanidins represent a potential natural therapeutic agent for preventing GDM-related ocular developmental abnormalities.